Mexico: Cannabis And Narcotics For Medicinal Use In Mexico

Last Updated: 13 March 2017
Article by Alejandro Luna, Alejandro Torres and Ingrid Ortiz

Cannabis and Narcotics for Medicinal use still have an uncertain status in Mexico. Regarding the medicinal use of cannabis there is still debate since the Mexican General Health Law still contains a provision that forbids activities and conducts in Mexico related with cannabis or its derivatives; with respect with other narcotics, there is also a prohibition within our Health Law. However, there are some precedents introducing the medicinal use of cannabis, and for other narcotics there are some approvals granted with our current legislation which have been in force for many years now.

The prohibition stablished in the Health Law mainly forbids plantation, cultivation, harvesting, elaboration, preparation, conditioning, acquisition, possession, trade, transportation in any form, prescription, supply, employment, use, consumption and, in general, any act related with narcotics or any products that contains them. The Health Law specifically prohibits prepared opium, for smoking, diacetylmorphine or heroin, its salts and preparations, cannabis sativa, indica and american or marijuana or opium poppy papaver somniferum, papaver bactreatum and erythroxilon novogratense or cocaine, in any form, derivatives or preparations. Additionally the Health Law stablishes a list of narcotics which approval is under the discretion of the Ministry of Health until they can be replaced in its therapeutic uses by other elements that, in their opinion, do not create dependency.

At the end of 2015, Mexican Supreme Court of Justice debated whether "recreational" use of cannabis should be authorized by the Federal Commission for Protection against Sanitary Risk (COFEPRIS) the Mexican Health Regulatory Agency.

Four members of a Mexican non-governmental organization (NGO) contested the refusal of a petition filed before COFEPRIS to plant, cultivate, prepare, possess and transport cannabis for "recreational" use. They argued in part that the basis of the refusal and the corresponding provisions of the Health Law violated the civil right to express one's personality and the rights of autonomy related to the human dignity that are recognized by the Mexican Constitution.

The District Court in charge of reviewing this Constitutional Action at the first stage dismissed the arguments. The NGO appealed, and due to the importance of the case, the appeal was taken up by the Mexican Supreme Court.

In brief, the Supreme Court Justices who decided the case declared certain articles of the Mexican General Health Law unconstitutional, as they foresee an extreme prohibition that attempts against these constitutional rights. The decision addressed that there is a minor health risk associated with cannabis, which is not severe and therefore does not require a strict prohibition like the one established by the related provisions of the Health Law.

The Supreme Court ordered COFEPRIS to issue the corresponding authorizations to these four members of the NGO, allowing them to plant, cultivate, prepare, possess and transport cannabis, but only for "recreational" use. The decision expressly excluded any act of commercialization, supply or any other activity that relates to disposal or distribution of cannabis. Finally, the Supreme Court's ruling considered that prohibiting the use of cannabis for "recreational" purposes is unconstitutional.

COFEPRIS complied with the decision on December 10, 2015, by granting to these four individuals the authorization to plant, cultivate, prepare, possess and transport cannabis for self-consumption on a "recreational" use, excluding any commercial activity. The case is significant, but the ruling has limited impact at the moment, as it is directed only to these four contesting individuals. Although highly persuasive, the decision does not constitute binding jurisprudence to other Courts of Law.

Despite the fact that the case was mainly focused to "recreational use" of cannabis the discussion among the Justices of the Mexican Supreme Court and the decision itself introduced the possibility of having approved clinical trials with cannabis, an eventual medicinal use of cannabis or pharmaceutical products with cannabis.

Notwithstanding the foregoing, at the time, there was another relevant case, wherein the importation and personal use of a drug with cannabidiol as an active ingredient was approved by COFEPRIS. Also, at the end of 2015, as a result of a constitutional action filed before a Federal District Court by the parents of a girl who suffered several epileptic seizures, in fact around 400 seizures, during a day, COFEPRIS was ordered to approve the importation and personal use of a drug with cannabis. The story behind the legal case moved our regulatory authorities, who showed they were willing to help by facilitating the importation of the medicine with cannabis, but also that they were open to discussion on the medicinal use of cannabis.

These precedents have made a great introduction to relevant topics such as the medical use of cannabis and other narcotics. They have set an interpretation of the "prohibitionist system" stablished in the Health Law stating that the Law actually does prohibit the "recreational" use of narcotics, including cannabis, but such state prohibition shall not apply to a medicinal use.

The decisions by the Supreme Court and other Federal Courts have had already considerable impact on the Mexican legal system as it relates to the use of this drug. Various levels of the Mexican Federal Government have begun a serious and formal debate regarding the recreational and medical use of cannabis; thus, other narcotics.

On April 21, 2016 the Mexican President Enrique Peña Nieto submitted a legislative proposal aimed to authorize cannabis for medicinal use. The Bill is aimed to authorize cannabis for medicinal use (personal use), including investigational activities and granting marketing authorizations for medicines which active ingredient is THC. The legislative proposal should be materialized by some modifications to the Health Law and the Federal Criminal Code. For this purpose, the Mexican Congress has created a Technical Committee designed for the eventual issuance of regulations regarding cannabis.

The proposal by the Mexican President was approved by the Senate on December 13, 2016. Although, the Bill is still pending for approval by the lower chamber of the Mexican Congress; considering the judicial precedents by the Mexican Supreme Court of Justice and other Federal Courts, there are great probabilities that the Bill is also approved by this chamber as well.

On the other hand, although there is still debate and the regulation is still under interpretation on case by case basis in most of the cases the "prohibitionist system" stablished in the General Health Law is applied.

Nevertheless, it is well known that there are approved pharmaceutical products which their active ingredient is a narcotic. Even, in one of the databases of the COFEPRIS' official website there are records of approved medicines with narcotics, such as Buprenorphine, Fentanyl, Sufentanil, Hydromorphone, Oxycodone, Tapentadol and Morphine. These are considered as narcotics in accordance to a list stated by a provision within the Health Law. Most of these substances are derived from opium considered by our Health Law as a narcotic, and broadly included in the prohibition. Furthermore, since 2006, COFEPRIS granted an approval for a medicine containing nabilone, which is a synthetic cannabinoid.

Considering the nature of such substances the prohibition should have been considered prior their approval, which did not happen. Therefore, the medicinal use was allowed under an exception to the rule, most probably due to the evidence of improvements and wellness that these substances provide to the patients.

In contrast, even though there is clinical evidence of the safety use of narcotics for medicinal use and that there are approved products using a therapeutic effect of a narcotics, any issue related to narcotics, it is still very sensitive in Mexico in all the levels of the government and society. Some of our authorities have spoken out against the medicinal use of cannabis or other narcotics in Mexico because they consider that narcotics represent a risk. They claim that our country does not have the required experience to govern and structure the legal frame to rule and enforce the use of narcotics and cannabis.

Although this approval of the Bill by the Senate and the precedents are a big step, we are only half way on having cannabis and other narcotics fully accepted and authorized for medicinal use in Mexico.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions